Article Sidebar
Published:
May 29, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy and safety of hydrogen gas versus standard therapy in Chinese patients with cerebral infarction: A pilot study
Abstract
Purpose: To evaluate the efficacy and safety of hydrogen (H2) gas versus standard therapy in Chinese patients with acute cerebral infarction (ACI)
Method: Chinese patients with ACI who had National Institutes of Health stroke scale (NIHSS) scores of 2 - 6 were enrolled and randomized to receive hydrogen gas through inhalation route or standard therapy. Hydrogen gas (3 %) was administered twice daily for 1 hour each over a period of 2 weeks using a facial mask (non-rebreathing). Standard treatment included edaravone 30 mg (iv every 12 h + antiplatelet drugs for 2 weeks. Efficacy endpoints were change in vital signs, change in NIHSS scores from baseline, change in magnetic resonance imaging (MRI) signal intensity, and improvement in rehabilitation index. Safety was also assessed.
Results: Data for 200 patients were analyzed. Patients treated with H2 gas had significantly greater improvement in NIHSS score than patients treated with standard therapy. This indicates that the neurological improvement was significantly greater in patients treated with H2 gas than those that received standard therapy for all the days tested (p < 0.05). The onset of NIHSS score reduction was faster in patients treated with H2 gas when compared to standard therapy. Furthermore, H2 gas demonstrated significant improvement in MRI signal Intensity score, which indicates that H2 gas was effective in recovery of infraction site.
Conclusion: The findings of this study show that H2 gas administered via the inhalation route is effective and safe in Chinese patients with acute cerebral infarction, and is therefore, superior to standard therapy.
